Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

Hypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1

Authors: Leah Morenos, Zac Chatterton, Jane L Ng, Minhee S Halemba, Mandy Parkinson-Bates, Francoise Mechinaud, Ngaire Elwood, Richard Saffery, Nicholas C Wong

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Background

Acute Myeloid Leukaemia (AML) is a highly heterogeneous disease. Studies in adult AML have identified epigenetic changes, specifically DNA methylation, associated with leukaemia subtype, age of onset and patient survival which highlights this heterogeneity. However, only limited DNA methylation studies have elucidated any associations in paediatric AML.

Methods

We interrogated DNA methylation on a cohort of paediatric AML FAB subtype M5 patients using the Illumina HumanMethylation450 (HM450) BeadChip, identifying a number of target genes with p <0.01 and Δβ >0.4 between leukaemic and matched remission (n = 20 primary leukaemic, n = 13 matched remission). Amongst those genes identified, we interrogate DLEU2 methylation using locus-specific SEQUENOM MassARRAY® EpiTYPER® and an increased validation cohort (n = 28 primary leukaemic, n = 14 matched remission, n = 17 additional non-leukaemic and cell lines). Following methylation analysis, expression studies were undertaken utilising the same patient samples for singleplex TaqMan gene and miRNA assays and relative expression comparisons.

Results

We identified differential DNA methylation at the DLEU2 locus, encompassing the tumour suppressor microRNA miR-15a/16-1 cluster. A number of HM450 probes spanning the DLEU2/Alt1 Transcriptional Start Site showed increased levels of methylation in leukaemia (average over all probes >60%) compared to disease-free haematopoietic cells and patient remission samples (<24%) (p < 0.001). Interestingly, DLEU2 mRNA down-regulation in leukaemic patients (p < 0.05) was independent of the embedded mature miR-15a/16-1 expression. To assess prognostic significance of DLEU2 DNA methylation, we stratified paediatric AML patients by their methylation status. A subset of patients recorded methylation values for DLEU2 akin to non-leukaemic specimens, specifically patients with sole trisomy 8 and/or chromosome 11 abnormalities. These patients also showed similar miR-15a/16-1 expression to non-leukaemic samples, and potential improved disease prognosis.

Conclusions

The DLEU2 locus and embedded miRNA cluster miR-15a/16-1 is commonly deleted in adult cancers and shown to induce leukaemogenesis, however in paediatric AML we found the region to be transcriptionally repressed. In combination, our data highlights the utility of interrogating DNA methylation and microRNA in combination with underlying genetic status to provide novel insights into AML biology.
Appendix
Available only for authorised users
Literature
1.
Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM: The biology of chronic myeloid leukemia. N Engl J Med. 1999, 341: 164-172. 10.1056/NEJM199907153410306.CrossRefPubMed
2.
Bennett JM, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposals for the classification of the acute leukaemias. Br J Haematol. 1976, 33: 451-458. 10.1111/j.1365-2141.1976.tb03563.x.CrossRefPubMed
3.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009, 114: 937-951. 10.1182/blood-2009-03-209262.CrossRefPubMed
4.
Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L, Campagne F, Mazumdar M, Greally JM, Valk PJM, Lowenberg B, Delwel R, Melnick AM: DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010, 17: 13-27. 10.1016/j.ccr.2009.11.020.PubMedCentralCrossRefPubMed
5.
Pui C-H, Carroll WL, Meshinchi S, Arceci RJ: Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011, 29: 551-565. 10.1200/JCO.2010.30.7405.PubMedCentralCrossRefPubMed
6.
Alvarez S, Suela J, Valencia A, Fernandez A, Wunderlich M, Agirre X, Prosper F, Martin-Subero JI, Maiques A, Acquadro F, Rodriguez Perales S, Calasanz MJ, Roman-Gomez J, Siebert R, Mulloy JC, Cervera J, Sanz MA, Esteller M, Cigudosa JC: DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS One. 2010, 5: e12197-10.1371/journal.pone.0012197.PubMedCentralCrossRefPubMed
7.
Gardiner-Garden M, Frommer M: CpG islands in vertebrate genomes. J Mol Biol. 1987, 196: 261-282. 10.1016/0022-2836(87)90689-9.CrossRefPubMed
8.
Galm O, Wilop S, Lüders C, Jost E, Gehbauer G, Herman JG, Osieka R: Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. Ann Hematol. 2005, 84: 39-46. 10.1007/s00277-005-0005-0.CrossRefPubMed
9.
Bird AP: DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16: 6-21. 10.1101/gad.947102.CrossRefPubMed
10.
11.
Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 2006, 6: 857-866. 10.1038/nrc1997.CrossRefPubMed
12.
Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N: Comninatorial microRNA target predictions. Nat Genet. 2005, 37: 495-500. 10.1038/ng1536.CrossRefPubMed
13.
14.
Tsai LM, Yu D: MicroRNAs in common diseases and potential therapeutic applications. Clin Exp Pharmacol Physiol. 2010, 37: 102-107. 10.1111/j.1440-1681.2009.05269.x.CrossRefPubMed
15.
Zhao G, Yu D, Weiss MJ: MicroRNAs in erythropoiesis. Curr Opin Hematol. 2010, 17: 155-162.PubMed
16.
Marti E, Pantano L, Banez-Coronel M, Llorens F, Minones-Moyano E, Porta S, Sumoy L, Ferrer I, Estivill X: A myriad of miRNA variants in control and Huntington’s disease brain regions detected by massively parallel sequencing. Nucleic Acids Res. 2010, 38: 7219-7235. 10.1093/nar/gkq575.PubMedCentralCrossRefPubMed
17.
Llorens F, Bañez-Coronel M, Pantano L, Antonio del Río J, Ferrer I, Estivill X, Martí E: A highly expressed miR-101 isomiR is a functional silencing small RNA. BMC Genomics. 2013, 14: 104-10.1186/1471-2164-14-104.PubMedCentralCrossRefPubMed
18.
Neilsen CT, Goodall GJ, Bracken CP: IsomiRs – the overlooked repertoire in the dynamic microRNAome. Trends Genet. 2012, 28: 544-549. 10.1016/j.tig.2012.07.005.CrossRefPubMed
19.
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Alder H, Rattan S, Keating MJ, Rai K, Rassenti L, Kipps TJ, Negrini M, Bullrich F, Croce CM: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002, 99: 15524-15529. 10.1073/pnas.242606799.PubMedCentralCrossRefPubMed
20.
Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, Ambesi-Impiombato A, Califano A, Migliazza A, Bhagat G, Dalla-Favera R: The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010, 17: 28-40. 10.1016/j.ccr.2009.11.019.CrossRefPubMed
21.
Daschkey S, Rottgers S, Giri A, Bradtke J, Teigler-Schlegel A, Meister G, Borkhardt A, Landgraf P: MicroRNAs distinguish cytogenetic subgroups in pediatric AML and contribute to complex regulatory networks in AML-relevant pathways. PLoS One. 2013, 8: e56334-10.1371/journal.pone.0056334.PubMedCentralCrossRefPubMed
22.
Agirre X, Martinez-Climent JA, Odero MD, Prosper F: Epigenetic regulation of miRNA genes in acute leukemia. Leukemia. 2012, 26: 395-403. 10.1038/leu.2011.344.CrossRefPubMed
23.
Chatterton Z, Morenos L, Saffery R, Craig JM, Ashley D, Wong NC: DNA methylation and miRNA expression profiling in childhood B cell acute lymphoblastic leukemia. Epigenomics. 2010, 2: 697-708. 10.2217/epi.10.39.CrossRefPubMed
24.
Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, Kaspers GJL, Heerema NA, Gerbing R, Lange BJ, Radich JP: Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006, 108: 3654-3661. 10.1182/blood-2006-03-009233.PubMedCentralCrossRefPubMed
25.
Juhl-Christensen C, Ommen HB, Aggerholm A, Lausen B, Kjeldsen E, Hasle H, Hokland P: Genetic and epigenetic similarities and differences between childhood and adult AML. Pediatr Blood Cancer. 2012, 58: 525-531. 10.1002/pbc.23397.CrossRefPubMed
26.
Liang D-C, Liu H-C, Yang C-P, Jaing T-H, Hung I-J, Yeh T-C, Chen S-H, Hou J-Y, Huang Y-J, Shih Y-S, Huang Y-H, Lin T-H, Shih L-Y: Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A. Blood. 2013, 121: 2988-2995. 10.1182/blood-2012-06-436782.CrossRefPubMed
27.
Tallman MS, Kim HT, Paietta E, Bennett JM, Dewald G, Cassileth PA, Wiernik PH, Rowe JM: Acute Monocytic Leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of Acute Myeloid Leukemia: a report from the eastern cooperative oncology group. J Clin Oncol. 2004, 22: 1276-1286. 10.1200/JCO.2004.08.060.CrossRefPubMed
28.
Bullinger L, Döhner K, Bair E, Fröhling S, Schlenk RF, Tibshirani R, Döhner H, Pollack JR: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med. 2004, 350: 1605-1616. 10.1056/NEJMoa031046.CrossRefPubMed
29.
Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T: AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood. 2003, 102: 2395-2402. 10.1182/blood-2003-02-0434.CrossRefPubMed
30.
Parker H, Rose-Zerilli MJJ, Parker A, Chaplin T, Wade R, Gardiner A, Griffiths M, Collins A, Young BD, Oscier DG, Strefford JC: 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia. 2011, 25: 489-497. 10.1038/leu.2010.288.CrossRefPubMed
31.
Bibikova M, Barnes BT, Chan T, Ho V, Klotzle B, Le JM, Delano D, Zhang L, Schroth GP, Gunderson KL, Fan J-B, Shen R: High density DNA methylation array with single CpG site resolution. Genomics. 2011, 98: 288-295. 10.1016/j.ygeno.2011.07.007.CrossRefPubMed
32.
Sarova I, Brezinova J, Zemanova Z, Bystricka D, Krejcik Z, Soukup P, Vydra J, Cermak J, Jonasova A, Michalova K: Characterization of chromosome 11 breakpoints and the areas of deletion and amplification in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer. 2013, 52: 619-635.CrossRefPubMed
33.
Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, Taccioli C, Zanesi N, Garzon R, Aqeilan RI, Alder H, Volinia S, Rassenti L, Liu X, Liu C-G, Kipps TJ, Negrini M, Croce CM: MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A. 2008, 105: 5166-5171. 10.1073/pnas.0800121105.PubMedCentralCrossRefPubMed
34.
Morenos L, Saffery R, Mechinaud F, Ashley D, Elwood N, Craig JM, Wong NC: Evaluation of MicroRNA expression in patient bone marrow aspirate slides. PLoS One. 2012, 7: e42951-10.1371/journal.pone.0042951.PubMedCentralCrossRefPubMed
35.
Monteys AM, Spengler RM, Wan J, Tecedor L, Lennox KA, Xing Y, Davidson BL: Structure and activity of putative intronic miRNA promoters. RNA. 2010, 16: 495-505. 10.1261/rna.1731910.PubMedCentralCrossRefPubMed
36.
Corcoran MM, Hammarsund M, Zhu C, Lerner M, Kapanadze B, Wilson B, Larsson C, Forsberg L, Ibbotson RE, Einhorn S, Oscier DG, Grander D, Sangfelt O: DLEU2 encodes an antisense RNA for the putative bicistronic RFP2/LEU5 gene in humans and mouse. Genes Chromosomes Cancer. 2004, 40: 285-297. 10.1002/gcc.20046.CrossRefPubMed
37.
Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, Xing R, Sun Z, Zheng X: miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res. 2008, 36: 5391-5404. 10.1093/nar/gkn522.PubMedCentralCrossRefPubMed
38.
Aqeilan RI, Calin GA, Croce CM: miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 2010, 17: 215-220. 10.1038/cdd.2009.69.CrossRefPubMed
39.
Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE: Oncogenic HER2D16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis. 2010, 31: 2049-2057. 10.1093/carcin/bgq192.PubMedCentralCrossRefPubMed
40.
Hanlon K, Rudin CE, Harries LW: Investigating the targets of MIR-15a and MIR-16-1 in patients with Chronic Lymphocytic Leukemia (CLL). PLoS One. 2009, 4: e7169-10.1371/journal.pone.0007169.PubMedCentralCrossRefPubMed
41.
Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem MR, Lin CP, Ribatti D, Rollins BJ, Witzig TE, Anderson KC, Ghobrial IM: MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009, 113: 6669-6680. 10.1182/blood-2009-01-198408.PubMedCentralCrossRefPubMed
42.
Zhao H, Kalota A, Jin S, Gewirtz AM: The c-myb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells. Blood. 2009, 113: 505-516. 10.1182/blood-2008-01-136218.PubMedCentralCrossRefPubMed
43.
Reutershan J, Cagnina RE, Chang D, Linden J, Ley K: Therapeutic anti-inflammatory effects of myeloid cell adenosine receptor A2a stimulation in lipopolysaccharide-induced lung injury. J Immunol. 2007, 179: 1254-1263. 10.4049/jimmunol.179.2.1254.CrossRefPubMed
44.
Wolff F, Loipetzberger A, Gruber W, Esterbauer H, Aberger F, Frischauf AM: Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase A-mediated GLI phosphorylation. Oncogene. 2013, 32: 5574-5581. 10.1038/onc.2013.343.PubMedCentralCrossRefPubMed
45.
Andersson A, Ritz C, Lindgren D, Eden P, Lassen C, Heldrup J, Olofsson T, Rade J, Fontes M, Porwit-MacDonald A, Behrendtz M, Hoglund M, Johansson B, Fioretos T: Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia. 2007, 21: 1198-1203. 10.1038/sj.leu.2404688.CrossRefPubMed
46.
Neff T, Armstrong SA: Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood. 2013, 121: 4847-4853. 10.1182/blood-2013-02-474833.PubMedCentralCrossRefPubMed
47.
Haferlach T, Schoch C, Schnittger S, Kern W, Loffler H, Hiddemann W: Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients. Br J Haematol. 2002, 118: 426-431. 10.1046/j.1365-2141.2002.03599.x.CrossRefPubMed
48.
Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J, Abdelali RB, Macintyre E, De Braekeleer E, De Braekeleer M, Delabesse E, de Oliveira MP, Cave H, Clappier E, van Dongen JJM, Balgobind BV, van den Heuvel-Eibrink MM, Beverloo HB, Panzer-Grumayer R, Teigler-Schlegel A, Harbott J, Kjeldsen E, Schnittger S, Koehl U, Gruhn B, Heidenreich O, Chan LC, Yip SF, Krzywinski M, Eckert C: New insights to the MLL recombinome of acute leukemias. Leukemia. 2009, 23: 1490-1499. 10.1038/leu.2009.33.CrossRefPubMed
49.
Schoch C, Kohlmann A, Dugas M, Kern W, Schnittger S, Haferlach T: Impact of trisomy 8 on expression of genes located on chromosome 8 in different AML Subgroups. Genes Chromosomes Cancer. 2006, 45: 1164-1168. 10.1002/gcc.20380.CrossRefPubMed
50.
Wong NC, Ashley D, Chatterton Z, Parkinson-Bates M, Ng HK, Halemba MS, Kowalczyk A, Bedo J, Wang Q, Bell K, Algar E, Craig JM, Saffery R: A distinct DNA methylation signature defines pediatric pre-B cell acute lymphoblastic leukemia. Epigenetics. 2012, 7: 535-541. 10.4161/epi.20193.CrossRefPubMed
51.
Rosenfeld C, Goutner A, Choquet C, Venuat AM, Kayibanda B, Pico JL: Phenotypic characterization of a unique non-T, non-B acute lymphoblastic leukaemia cell line. Nature. 1977, 267: 841-843. 10.1038/267841a0.CrossRefPubMed
52.
Kaplan J, Mastrangelo R, Peterson WDJ: Childhood lymphoblastic lymphoma, a cancer of Thymus-derived lymphocytes. Cancer Res. 1974, 34: 521-525.PubMed
53.
Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N: Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood. 1991, 77: 2031-2036.PubMed
54.
Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K: Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer. 1980, 26: 171-176. 10.1002/ijc.2910260208.CrossRefPubMed
55.
Lange B, Valtieri M, Santoli D, Caracciolo D, Mavilio F, Gemperlein I, Griffin C, Emanuel B, Finan J, Nowell P: Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood. 1987, 70: 192-199.PubMed
56.
Du P, Kibbe WA, Lin SM: lumi: a pipeline for processing Illumina microarray. Bioinformatics. 2008, 24: 1547-1548. 10.1093/bioinformatics/btn224.CrossRefPubMed
57.
Smyth GK: limma: Linear Models for Microarray Data. 2005, New York, USA: Springer
58.
Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z: GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics. 2009, 10: 48-10.1186/1471-2105-10-48.PubMedCentralCrossRefPubMed
59.
Li J, Smyth P, Flavin R, Cahill S, Denning K, Aherne S, Guenther SM, O’Leary JJ, Sheils O: Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol. 2007, 7: 36-10.1186/1472-6750-7-36.PubMedCentralCrossRefPubMed
60.
Borze I, Guled M, Musse S, Raunio A, Elonen E, Saarinen-Pihkala U, Karjalainen-Lindsberg M-L, Lahti L, Knuutila S: MicroRNA microarrays on archive bone marrow core biopsies of leukemias—Method validation. Leuk Res. 2011, 35: 188-195. 10.1016/j.leukres.2010.08.005.CrossRefPubMed
61.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-DDCt method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.CrossRefPubMed
62.
63.
64.
Dweep H, Sticht C, Pandey P, Gretz N: miRWalk–database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform. 2011, 44: 839-847. 10.1016/j.jbi.2011.05.002.CrossRefPubMed
Metadata
Title
Hypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1
Authors
Leah Morenos
Zac Chatterton
Jane L Ng
Minhee S Halemba
Mandy Parkinson-Bates
Francoise Mechinaud
Ngaire Elwood
Richard Saffery
Nicholas C Wong
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-123

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue

Research

OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets

Research

miR-2909-mediated regulation of KLF4: a novel molecular mechanism for differentiating between B-cell and T-cell pediatric acute lymphoblastic leukemias

Research

mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells

Research

Small nucleolar RNA signatures of lung tumor-initiating cells

Research

ISL-1 is overexpressed in non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/p-c-Jun/ISL-1 complex

Research

The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits